Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome

Study limitation reported by the research below: “The 'impact flag' of practice changing reflects the novelty of the RIPK3 inhibition finding and RNASE1 as a biomarker, but this is preclinical — no clinical trials in VEXAS patients have been conducted yet.”